BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 11070170)

  • 21. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading.
    Denzin LK; Cresswell P
    Cell; 1995 Jul; 82(1):155-65. PubMed ID: 7606781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Negative regulation by HLA-DO of MHC class II-restricted antigen processing.
    Denzin LK; Sant'Angelo DB; Hammond C; Surman MJ; Cresswell P
    Science; 1997 Oct; 278(5335):106-9. PubMed ID: 9311912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
    Ghosh P; Amaya M; Mellins E; Wiley DC
    Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides.
    Avva RR; Cresswell P
    Immunity; 1994 Dec; 1(9):763-74. PubMed ID: 7895165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HLA-DM recognizes the flexible conformation of major histocompatibility complex class II.
    Chou CL; Sadegh-Nasseri S
    J Exp Med; 2000 Dec; 192(12):1697-706. PubMed ID: 11120767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissection of the HLA-DR4 peptide repertoire in endocrine epithelial cells: strong influence of invariant chain and HLA-DM expression on the nature of ligands.
    Muntasell A; Carrascal M; Alvarez I; Serradell L; van Veelen P; Verreck FA; Koning F; Abian J; Jaraquemada D
    J Immunol; 2004 Jul; 173(2):1085-93. PubMed ID: 15240697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HLA-DM stabilizes empty HLA-DR molecules in a chaperone-like fashion.
    vogt AB; Moldenhauer G; Hämmerling GJ; Kropshofer H
    Immunol Lett; 1997 Jun; 57(1-3):209-11. PubMed ID: 9232453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between HLA-DM and HLA-DR in vivo.
    Sanderson F; Thomas C; Neefjes J; Trowsdale J
    Immunity; 1996 Jan; 4(1):87-96. PubMed ID: 8574855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
    Pezeshki AM; Azar GA; Mourad W; Routy JP; Boulassel MR; Denzin LK; Thibodeau J
    Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules.
    Hitzel C; Koch N
    Mol Immunol; 1996 Jan; 33(1):25-31. PubMed ID: 8604221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Self-release of CLIP in peptide loading of HLA-DR molecules.
    Kropshofer H; Vogt AB; Stern LJ; Hämmerling GJ
    Science; 1995 Nov; 270(5240):1357-9. PubMed ID: 7481823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules.
    Kropshofer H; Vogt AB; Thery C; Armandola EA; Li BC; Moldenhauer G; Amigorena S; Hämmerling GJ
    EMBO J; 1998 Jun; 17(11):2971-81. PubMed ID: 9606180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracellular and cell surface heterotypic associations of human leukocyte antigen-DR and human invariant chain.
    Triantafilou K; Triantafilou M; Wilson KM; Cherry RJ; Fernandez N
    Hum Immunol; 1999 Nov; 60(11):1101-12. PubMed ID: 10600008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced interaction of HLA-DM with HLA-DR in enlarged vacuoles of hereditary and infectious lysosomal diseases.
    Lem L; Riethof DA; Scidmore-Carlson M; Griffiths GM; Hackstadt T; Brodsky FM
    J Immunol; 1999 Jan; 162(1):523-32. PubMed ID: 9886429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction between HLA-DM and HLA-DR involves regions that undergo conformational changes at lysosomal pH.
    Ullrich HJ; Döring K; Grüneberg U; Jähnig F; Trowsdale J; van Ham SM
    Proc Natl Acad Sci U S A; 1997 Nov; 94(24):13163-8. PubMed ID: 9371817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The intracellular transport of MHC class II molecules in the absence of HLA-DM.
    Green JM; DeMars R; Xu X; Pierce SK
    J Immunol; 1995 Oct; 155(8):3759-68. PubMed ID: 7561080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accessory molecules for MHC class II peptide loading.
    Busch R; Doebele RC; Patil NS; Pashine A; Mellins ED
    Curr Opin Immunol; 2000 Feb; 12(1):99-106. PubMed ID: 10679402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression.
    Busch R; Rinderknecht CH; Roh S; Lee AW; Harding JJ; Burster T; Hornell TM; Mellins ED
    Immunol Rev; 2005 Oct; 207():242-60. PubMed ID: 16181341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Formation of two peptide/MHC II isomers is catalyzed differentially by HLA-DM.
    Belmares MP; Busch R; Mellins ED; McConnell HM
    Biochemistry; 2003 Jan; 42(3):838-47. PubMed ID: 12534297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides.
    Mellins E; Cameron P; Amaya M; Goodman S; Pious D; Smith L; Arp B
    J Exp Med; 1994 Feb; 179(2):541-9. PubMed ID: 8294865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.